UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. ~~20549~~20549FORM 10-Q(Mark One)[x] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended December 31, 2009OR[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to _______________ Commission file number ______________ PURE PHARMACEUTICALS CORPORATION(Exact name of Registrant as Specified in Its Charter)

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2009

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________________to ___________________

Commission file number __________________________________________________________

PURE PHARMACEUTICALS CORPORATION (Exact name of Registrant as Specified in Its Charter)

NEVADA	45-0476087
(State or Other Jurisdiction of Incorporation or	(IRS Employer Identification No.)
Organization)


P.O. BOX 55, 1594 STONE MILL PARK,
BELLONA, NY	14415
(Address of Principal Executive Offices)	(Zip Code)

(315) 849-2822
(Registrant’s Telephone Number, Including Area Code)

~~___________________________________________________~~________________(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [Xx] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the exchange Act. (Check One)

Large Accelerated Filer [ ]

Accelerated Filer [ ]

Non-Accelerated Filer [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [Xx] No [ ]

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

Yes [ ] No [ ]

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

*Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [ ] Smaller reporting company [Xx] (Do not check if a smaller reporting company)

PART ~~1 FINANCIAL~~ 1FINANCIAL INFORMATION

Item 1. Financial Statements.

PURE PHARMACEUTICAL CORPORATION
(A Development Stage Company)

~~NINE~~FINANCIAL STATEMENTSDECEMBER ~~MONTHS ENDED JUNE 30~~31, 2009

PURE PHARMACEUTICAL CORPORATION

(A Development Stage Company)

BALANCE SHEETS

(Unaudited)

	June 30, 2009		September 30, 2008
	December 31,		September 30,
	(Unaudited)		(Audited)
	2009		2009
	- $ -		- $ -
ASSETS
Current
Cash	~~859~~6,510		128,~~459~~573
	859		12,459
	6,510		8,573
LIABILITIES
Current
Accounts payable and accrued liabilities	1824,~~734~~507		4630,~~213~~771
	18,734		46,213
Long-term loans	43,431		59,314
LONG TERM DEBT	58,108		40,000
	67,938		90,085
	76,842		86,213
STOCKHOLDERS’ DEFICIT
STOCKHOLDERS’ EQUITY
Common Stock (Note 2)
Authorized:
Authorized: 100,000,000 common shares with a par value of $0.001 Issued and Outstanding: 12,600,000 common shares (September 30, 2009– 12,600,000)	12,600		12,600
100,000,000 common shares
Additional paid up capital	223,800		191,400
With a par value of $0.001
Accumulated other comprehensive income	2,439		2,439
Issued and Outstanding:
Deficit accumulated during the development stage	(300,267	)	(287,951	)
12,600,000 common shares
	(61,428	)	(81,512	)
(September 30, 2008 – 12,600,000)	12,600		12,600
	6,510		8,573
Additional paid up capital	169,000		161,800
Accumulated comprehensive income	3,605		271
Deficit accumulated during the development stage	(261,188	)	( 248,425	)
	(75,983	)	(73,754	)
	859		12,459

– See Accompanying Notes –

PURE PHARMACEUTICAL CORPORATION

(A Development Stage Company)

STATEMENTS OF OPERATIONS

(Unaudited)

									Period from
					Cumulative
									September 24,
					from
									2004
					September 24,
	Three		Three		Nine		Nine		(Inception) to
	Three months		Three months		2004
	months ended		months ended		months ended		months ended		June 30,
	ended		ended		(Inception) to
	June 30, 2009		June 30, 2008		June 30, 2009		June 30, 2008		2009
	December 31,		December 31,		December 31,
	(Unaudited)		(Unaudited)		(Unaudited)		(Unaudited)		(Unaudited)
	2009		2008		2009
	- $ -		- $ -		- $ -		~~- $ -~~		~~- $ -~~
Revenue	-		-4,000		820,~~310~~398		-		~~20,398~~
Cost of sales	-		-		-9,670		-		~~9,670~~
	-		-4,000		810,~~310~~728		-		~~10,728~~
Expenses
Financing fees	-		-		-5,600		-		~~5,600~~
General and
General and administrative	11,516		5,343		295,541
administrative	3,484		9,703		21,073		46,698		266,316
Interest on long-term loans	800		800		4,724
Net loss	(3,484	)	(9,703	)	(12,763	)	(46,698	)	(261,188	)
Write-down of inventory	-		-		5,130
Basic and diluted loss
Net loss	(12,316	)	(2,143	)	(300,267	)
per share	(0.00	)	(0.00	)	(0.00	)	(0.00	)
Loss per share – basic and diluted	(0.00	)	(0.00	)
Weighted average
Weighted average number of common shares outstanding- basic and dilutive	12,600,000		12,600,000
number of common
shares outstanding	12,600,000		12,600,000		12,600,000		12,600,000

– See Accompanying Notes –

PURE PHARMACEUTICAL CORPORATION

(A Development Stage Company)

STATEMENTS OF CASH FLOWS

(Unaudited)

					Period from
		Three			Three		Cumulative from
	Nine months		Nine months		September 24, 2004
		months			months		September 24, 2004
	~~ended~~	ended	~~ended~~		~~(Inception) to~~ended		(Inception) to
	June 30, 2009		June 30, 2008		June 30, 2009
		December			December		December 31,
	(Unaudited)		(Unaudited)		(Unaudited)
		31, 2009			31, 2008		2009
	~~- $ -~~	- $ -	~~- $ -~~		- $ -		- $ -
Cash Flows From Operating Activities
Net loss	~~(12,763~~	)(12,316	~~(46,698~~)	)	(~~261~~2,~~188~~143	)	(300,267	)
Non-cash administrative expenses	11,084		7,200		49,484
Non-cash items:
Net change in non-cash working capital
Accrued interest on long term loan		800			800		4,724
balance:
Donated capital		2,400			2,400		50,400
Accounts payable	(27,480	)	(6,490	)	18,734
Write down of inventory		-			-		5,130
Net cash used in operations	(29,159	)	(45,988	)	(192,970	)
Change in non-cash working capital items:
Cash Flows From Financing Activities
Inventory		-			-		(5,130	)
Capital stock issued	-		-		136,000
Accounts payable and accrued liabilities		(6,264	)		(263	)	54,507
Long term debt	14,224		40,000		54,224
Net cash used in operating activities		15,380			794		(190,636	)
Net cash provided by financing activities	14,224		40,000		190,224
Cash Flows From Financing Activities
Effect of exchange rate changes	3,335		(344	)	3,605
Proceeds from (repayment of) long-term loans		(16,683	)		-		38,707
Increase (Decrease) In Cash	(11,600	)	(6,332	)	859
Donated capital		30,000			-		50,000
Cash, beginning	12,459		28,906		-
Capital stock issued for cash		-			-		136,000
Cash, ending	859		22,574		859
Net cash provided by financing activities		(13,317	)		-		224,707
Supplementary Cash Flow
Effect of exchange rate changes		-			(29	)	2,439
Information:
Increase (Decrease) In Cash		(2,063	)		(765	)	6,510
Cash paid for:
Cash, beginning		8,573			12,459		-
Interest	-		-		-
Cash, ending		6,510			13,224		6,510
Income taxes	-		-		-
Supplementary Cash Flow Information:
Cash paid for:
Interest		-			-		-
Income taxes		-			-		-

- See Accompanying Notes -

PURE PHARMACEUTICAL CORPORATION (A Development Stage Company) NOTE TO THE FINANCIAL STATEMENTS ~~JUNE~~DECEMBER 3031, 2009 (Unaudited)

1.	BASIS OF PRESENTATION
	Unaudited Interim Financial Statements
	Unaudited Interim Consolidated Financial Statements
	The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission. They may not include all information and footnotes required by generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there has been no material changes in the information disclosed in the notes to the financial statements for the year ended September 30, 2008, included in the Company’s Form 10-KSB filed with the Securities and Exchange Commission. The unaudited interim financial statements should be read in conjunction with those financial statements included in the Form 10-KSB. In the opinion of Management, all adjustments considered necessary for a fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the nine months ended June 30, 2009 are not necessarily indicative of the results that may be expected for the year ending September 30, 2009.
	The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission. They may not include all information and footnotes required by generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there has been no material changes in the information disclosed in the notes to the financial statements for the year ended September 30, 2009, included in the Company’s Form 10-K filed with the Securities and Exchange Commission. The unaudited interim financial statements should be read in conjunction with those financial statements included in the Form 10-K. In the opinion of Management, all adjustments considered necessary for a fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three months ended December, 31, 2009 are not necessarily indicative of the results that may be expected for the year ending September 30, 2010.
2.	SUBSEQUENT EVENT On July 23, 2009 the Company entered into a non binding letter of intent ("LOI"). The LOI provides that the Company may enter into a merger or share exchange pursuant to the terms of a definitive agreement which the parties have agreed to negotiate in good faith. In connection with the LOI, the Company received a deposit of $50,000.
	We evaluated events occurring between the end of our fiscal quarter December 31, 2009 and February 12, 2010 when the financial statements were issued.
2.	COMMON STOCK
	During the three months ended December 31, 2009, the Company received $30,000 as the second installment of the $50,000 non-refundable required by the Letter of Intent (“LOI) entered into by the Company with 7167415 Canada Inc. on July 21, 2009. The LOI expired on July 23, 2009 and a definitive agreement was not entered into. Accordingly, the non-refundable deposit has been recorded as donated capital.

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations.

Forward Looking Statements

In addition to historical information, the following discussion and other parts of this document may contain forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," or "continue," the negative of such terms or other comparable terminology. These statements are only predictions. The events described in forward looking statements we make in this Form 10-Q may not occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We caution you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties risks and other influences, many of which are beyond our control that may influence the accuracy of the statements and the projections upon which the statements are based. Moreover, neither we nor any other person assume responsibility for the accuracy and completeness of the forward-looking statements. Except as may be required by law, we undertake no obligation to publicly update any of the forward-looking statements after the date of this report to conform such statements to actual results or to changes in our expectations.

Actual results could differ materially from those anticipated by such forward-looking statements. The following discussion should be read in conjunction with the financial statements as well as other financial information appearing elsewhere in this document. Readers are also urged to carefully review and consider the various disclosures made by us which attempt to advise interested parties of the factors which affect our business.

Our Business

The Company was formed in order to seek business opportunities in the area of expertise of the Company's principal stockholder, Mr. Roger Gordon, being biological and/or medical products for animal use. The Company principally operated in the field of generic animal health and nutrition products, specifically medicated feed additives (MFAs). MFAs are used preventively and therapeutically in animal feed to prevent disease and foster growth in livestock. In North America, 90% of all feed to animals contain MFAs, but has been on the decrease in the last five years. Our intended customers operate in the poultry, swine and cattle markets. The Company has historically focused its efforts on generic MFAs, as they have come off patent, ~~therefore~~ therefore making them more economical to register with requisite regulators in the United States and Canada, with a view to bringing the products to market.

The Company ~~continued~~ceased to market aan under licensed related-party owned MFA, Oxytetracycline, and ~~are~~is incontinuing ~~the~~its ~~exploratory~~discussions ~~phase~~with ofthird ~~identifying~~parties in ~~generic~~connection ~~MFAs that it intended to test and register~~ with ~~regulatory authorities with~~ a ~~view~~possible tomerger ~~being~~agreement ~~granted~~or ashare ~~DIN~~exchange orpursuant ~~similar~~to ~~authorization~~which tocontrol ~~market~~of ~~such~~the ~~MFAs~~Company inmay ~~North~~be ~~America~~sold ~~(henceforth,~~to ~~the~~such ~~identification~~third ~~process)~~parties. As market dynamics have undergone significant systemic changes over the past ~~three~~four years with the emergence of avian flu and the attendant fall in poultry ~~consumption~~ consumption worldwide, management ~~has~~realized ~~had to conduct~~ the identification process for new MFAs cannot be done with ~~due~~the ~~deliberation~~limited resources of the Company. Furthermore, with the prices of feed, particularly maize, at record high prices, out intended customers have been hesitant to add to their expenses.

The Company's activities to date have been primarily organizational in nature and as a result the Company must be considered to be in its developmental stage. The Company relies solely on the efforts of its management and director and has no employees, owns few business assets, technology or real estate and since inception has been primarily involved in developing and refining its business plan, preliminarily

~~since~~identifying ~~inception~~generic ~~has~~MFAs ~~been~~for ~~primarily~~registration, ~~involved~~raising ~~in developing its~~initial ~~business plan~~capital, ~~preliminarily~~and ~~identifying~~looking ~~generic MFAs~~ for ~~registration,~~other ~~and raising~~potential ~~initial~~shareholder ~~capital~~maximizing corporate actions.

Management previously determined to refocus, assess and identify alternative business strategies due to prolonged high prices of maize and other inputs and other general systemic economic conditions affecting the business of the Company.

Recent Developments

~~Sales~~The ~~have~~Company ~~decreased~~has ~~year~~booked ~~over~~no ~~year~~sales ~~due~~for tothis ~~the~~period ~~volatility~~ and had ~~increasing~~received ~~prices~~$30,000 ofdonated ~~maize.~~capital from an outside third party during the period. As a result of the prolonged high prices of inputs and other general conditions affecting the business of the Company, management determined, earlier in its fiscal year, to refocus, assess and identify alternative business strategies. In July 2008, the Company was quoted on the OTC Bulletin Board under the symbol “PPMA”. The Company is continuing its discussions with third parties in connection with a possible merger or share exchange pursuant to which control of the Company may be sold to such third parties.

OnResults ~~July 23, 2009 the Company entered into a non binding letter~~ of ~~intent~~Operations ("LOI"). The LOI provides that the Company may enter into a merger or share exchange pursuant to the terms of a definitive agreement which the parties have agreed to negotiate in good faith. In connection with the LOI, the Company received a deposit of $50,000.

Results of Operations for the Period ended December 31, 2009

~~Results~~The ofCompany ~~Operations~~did not earn any revenues in the previous 3 months ended December 31, 2009. We incurred operating expenses in the amount of $12,316 for the ~~Period~~three months ended ~~June~~December 3031, 2009. Our net loss for the three months ended was $12,316 as compared to net loss of $2,143 for the three months ended December 31, 2008. As at December 31, 2009 we had cash of $6,510. The Company’s losses stem from the payment of professional fees.

The ~~company~~Company ~~did~~ceased ~~not~~its ~~earn~~sales ~~any~~and ~~revenues~~marketing inof the ~~three~~Company’s Oxytetracyline ~~months~~as ~~ended~~well as the process of the Company pursuing opportunities in ~~June~~the 30generic MFAs areas. As stated in the prior quarter, ~~2009~~the ~~and~~Company ~~incurred~~will ~~operating~~not ~~expenses~~be importing infurther Oxytetracyline from the ~~amount~~People’s Republic of ~~$3,484~~China which is idleling production until the overall economic situation improves; and our factory suppliers have remained dormant and have not provided an ETA as to when production would resume. ~~Our~~Due ~~net~~to acute fluctuations in the price of key ~~loss~~ingredients; corn and soybeans; the ability for producers to manage price pressure is severely challenged. Corn prices see-sawed and surged 3 to-5 fold in the ~~three~~last 24 months ~~ended~~to ~~June~~$750 30USD per bushel mid 2008. Since its high, the price has continued its volatility and as an example from June 1st to December 31th 2009 ~~was~~prices swung 22% in 30 days from $~~3,484~~425 USD per bushel to $350 USD per bushel. AsFarmers atand ~~June~~buyers 30are taking a wait and see approach and farmers in particular are not selling their crops and trying to time the market. Management and analysts believe the competition for corn, once viewed as a commodity and now viewed as a matter of national security for countries, is here to stay. Though prices have dropped in the first six months of 2009, wethe price is still double that of three years ago in January 2006, and ~~had~~have ~~cash~~trended upwards in the last half of ~~$859.~~2009 The ~~company’s~~use ~~losses~~of ~~stem~~corn ~~from~~for the ~~payment~~production of ethanol and the agricultural polices of ~~professional~~leading petroleum usage countries ~~fees~~continue to exert price and demand pressures on the market1. Also confounding the problem is worldwide health concerns and reaction to animal borne disease transmission to humans.

~~Sales~~Due ~~and~~to ~~marketing of~~ the ~~company’s~~prolonged ~~Oxytetracyline~~uncertainty and ~~the process~~relative ofhigh ~~the company pursuing opportunities in the generic MFAs areas continue~~historic toprices beof ~~very~~inputs, ~~difficult~~ this ~~quarter.~~upward Ascycle ~~stated~~has inlasted ~~the~~for ~~prior~~3 ~~quarter~~years, weand dogeneral ~~not~~economic ~~anticipate~~conditions ~~importing~~which ~~more~~are ~~product~~effecting in the ~~next~~business ~~six months going forward as the manufacturer in the People’s Republic~~ of ~~China is idleling production until~~ the ~~overall~~ ~~economic situation improves~~company; ~~and~~management our factory suppliers have remained dormant and have not provided an estimated time as to when production would resume. Due to acute fluctuations in the price of key ingredients; corn and soybeans; the ability of producers to manage price pressure is severely challenged. Corn prices fluctuated and surged 3 to-5 fold in the last 24 months to $750 USD per bushel by mid 2008. Since its high, the price has ~~continued its~~ ~~volatility~~determined ~~and, as an example, from June 1st~~ to June 30th 2009 prices swung 19% in 30 days from $425 USD per bushel to $350 USD per bushel. Farmers and buyers are taking a wait and see approach and farmers in particular are not selling their crops and trying to time the market. Management and analysts believe the competition for cornrefocus, ~~once viewed as a commodity and now viewed as a matter of national security for countries~~assess, ~~is here to stay. Though prices have dropped in the first six months of 2009, the price is still double that of three years ago in January 2006. The use of corn for the production of ethanol~~ and ~~the~~identify ~~agricultural~~alternative ~~policies~~business ~~of leading petroleum usage countries continue to exert price and demand pressures on the market1~~strategies. ~~Also confounding the problem is worldwide health concerns and reaction to animal borne disease transmission to humans.~~

~~Due~~1 to the prolonged uncertainty and relative high historic prices of inputs, this upward cycle has lasted for three years, and general economic conditions which are effecting the business of the company; management has determined to refocus, assess, and identify alternative business strategieshttp://www.financialpost.com/story.html?id=311350

Liquidity and Capital Resources

Our cash reserves of $~~859~~6,510 as at ~~June~~December 3031, 2009 ($128,~~459~~573 as at September 30, ~~2008~~2009) are not sufficient to meet our funding needs beyond the next nine-month period. To this effect, the ~~company~~Company will need to seek ~~additional~~ additional funding in the near future. We currently do not have a specific plan ~~for~~ for obtaining such funding, however, we anticipate that any additional funding will be in the form of equity financing from the sale of our common stock and/or loans (interest or convertible). We currently do not have any arrangements in place for any future equity financing. We may also seek to obtain short-term loans from our directors, although no such arrangements have as yet been made. There can be no assurance that we will be able to raise sufficient funding from the sale of our common stock or through director loans to meet our funding needs after the next nine months.

1The ~~http://www~~Independent Auditor's Report to our audited financial statements for the period ended September 30, 2009 indicated that there are a number of factors that raise substantial doubt about our ability to continue as a going concern.~~financialpost~~ Such factors identified in the report include that we need to generate profitable operations and are in need of obtaining adequate financing.~~com/story~~ For these and other related reasons our auditors believe that there is substantial doubt that we will be able to continue as a going concern.~~html?id=311350~~

~~however,~~Comparison ~~we anticipate that any additional funding will be in the form~~ of ~~equity~~Interim ~~financing~~Financial from the sale of our common stock and/or loans (interest or convertible). We currently do not have any arrangements in place for any future equity financing. We may also seek to obtain short-term loans from our directors, although no such arrangements have as yet been made. There can be no assurance that we will be able to raise sufficient funding from the sale of our common stock or through director loans to meet our funding needs after the next nine months.Results

~~The~~As ~~Independent~~at ~~Auditor's~~December ~~Report~~31, ~~to our audited financial statements for the period ended September 30~~2009, ~~2008~~accounts ~~indicated~~payable ~~that~~balance ~~there~~is ~~are a~~$24,507 ~~number~~compared ~~of factors that raise substantial doubt about our ability~~ to ~~continue~~$30,771 as a ~~going~~at ~~concern.~~September ~~Such~~30, ~~factors identified in the report include that we need to generate profitable operations and are in need of obtaining adequate financing~~2009. ~~For~~ ~~these~~Loan ~~and~~payable ~~other~~balance ~~related reasons our auditors believe that there~~ is ~~substantial~~$43,431 ~~doubt~~compared ~~that we will be able~~ to ~~continue~~$59,314 as aat ~~going~~September ~~concern~~30, 2009.

~~Comparison~~Sales ofhave ~~Interim~~decreased ~~Financial~~year ~~Results~~over year due to the increasing and volatility prices of maize.

AsOff-Balance atSheet ~~June 30, 2009, our accounts payable balance was $18,734 compared to $46,213 as at September 30, 2008. Our loan payable balance was $58,108 compared to $40,000 as at September 30, 2008.~~Arrangements

~~Sales~~The Company does not have ~~decreased~~any ~~year~~off-balance ~~over~~sheet ~~year~~arrangements that ~~due~~have or are reasonably likely to have a current or future effect on the small ~~increasing~~business ~~and~~issuer's financial condition, changes in financial condition, ~~volatility~~revenues ~~prices~~or expenses, results of ~~maize~~operations, liquidity, capital expenditures or capital resources that is material to investors.

~~Off-Balance~~Item ~~Sheet~~3. ~~Arrangements~~Quantitative and Qualitative Disclosures About Market Risk.

~~The~~Not Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the small business issuer's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investorsapplicable.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4.

Controls and Procedures.

Evaluation of Disclosure Controls and Procedures. The Company's Management under the supervision and with the participation of the Principal Executive Officer and the Principal Financial Officer are responsible for establishing and maintaining "disclosure controls and procedures" (as defined in the Exchange Act) for the Company. Based on their evaluation of the Company's disclosure controls and procedures as of ~~June~~December 3031, 2009, the Company's Management has concluded that the Company's disclosure controls and ~~procedures~~ procedures were effective to ensure that the information required to be disclosed by the Company under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the Exchange Act and accumulated and communicated to the Company's Management, including the Principal Executive Officer and the Principal Financial Officer, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting. During the fiscal quarter ending ~~June~~December 3031, 2009, there were no changes in ~~the~~ the Company's internal control over financial reporting during the period ~~covered by this report that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.~~

~~Limitations~~covered onby ~~the~~this ~~Effectiveness~~report ofthat ~~Controls.~~have Amaterially ~~control system~~affected, noor ~~matter~~are reasonably ~~how~~likely ~~well~~to ~~conceived~~materially ~~and operated~~affect, ~~can provide only reasonable, not absolute, assurance that~~ the ~~objectives~~Company's ofinternal ~~the~~ control ~~system~~over financial ~~are~~ reporting.

~~met~~Limitations on the Effectiveness of Controls. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. The Company's disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives, and the Principal Executive Officer and the Principal Financial Officer have concluded that these controls and procedures are effective at the "reasonable assurance" level.

Item 4T.

Controls and Procedures.

The Company's management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

Our internal control over financial reporting includes those policies and procedures that:

Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and the director; and
Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on the financial statements.

As required by Rule 13a-15 and 15d-15 under the Securities and Exchange Act of 1934, Management assessed the effectiveness of the Company’s internal control over financial reporting as of ~~June~~December 3031, 2009. Based on this assessment, the Company's management has concluded that the Company maintained effective internal control over financial reporting as of ~~June~~December 3031, 2009, the ~~end~~ end of the period covered by this quarterly report.

This quarterly report does not include an attestation report of the company's registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the company's registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission ("SEC") that permit the Company to provide only management's report in this quarterly report.

Changes in Internal Control over Financial Reporting. Management has evaluated whether any changes in our internal control over financial reporting that occurred during our last fiscal quarter have materially effected, or reasonably likely to materially effect our internal control over financial reporting. Based on the evaluation we conducted, management has concluded that during the fiscal quarter ending ~~June~~December 3031, 2009, there were no changes in the Company's internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. The Company's disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives, and the Principal Executive Officer and the Principal Financial Officer have concluded that these controls and procedures are effective at the "reasonable assurance" level.

~~Financial~~PART ~~Officer~~II ~~have~~– ~~concluded~~OTHER ~~that these controls and procedures are effective at the "reasonable assurance" level.~~INFORMATION

~~PART~~Item II1. –Legal ~~OTHER INFORMATION~~Proceedings.

~~Item~~We 1.are ~~Legal~~not ~~Proceedings~~currently a party to any legal proceedings.

WeItem ~~are~~1A. ~~not~~Risk ~~currently a party to any legal proceedings~~Factors.

~~Item~~Not 1Aapplicable. ~~Risk Factors.~~

~~Not~~Item ~~applicable~~2. Unregistered Sales of Equity Securities and Use of Proceeds.

~~Item 2~~None. ~~Unregistered Sales of Equity Securities and Use of Proceeds.~~

~~None~~Item 3. Defaults Upon Senior Securities.

~~Item 3~~None. ~~Defaults Upon Senior Securities.~~

~~None~~Item 4. Submission of Matters to a Vote of Security Holders.

~~Item~~No 4.matters ~~Submission~~have ofbeen ~~Matters~~submitted to our security holders for a vote, ~~Vote~~through the solicitation of ~~Security~~proxies ~~Holders~~or otherwise, during the quarterly period ended December 31, 2009.

NoItem ~~matters~~5. ~~have~~Other ~~been submitted to our security holders for a vote, through the solicitation of proxies or otherwise, during the quarterly period ended June 30, 2009~~Information.

~~Item 5~~None. ~~Other Information.~~

~~None~~Item 6. Exhibits.

Item 6. Exhibits.

31.1	Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2	Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1	Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

31.1	Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

~~SIGNATURES~~In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		PURE PHARMACEUTICALS CORPORATION
		(Registrant)


Date: February 12, 2010		By: /s/ Roger Gordon
		Roger Gordon
		President, Principal Executive Officer and Director



Date: February 12, 2010		By: /s/ Charlie Lee
		Charlie Lee
		Secretary and Principal Accounting Officer

		PURE PHARMACEUTICALS CORPORATION
		(Registrant)
Date:	August 14, 2009	By: /s/ Roger Gordon
		Roger Gordon
		President, Principal Executive Officer and Director
Date:	August 14, 2009	By: /s/ Charlie Lee
		Charlie Lee
		Secretary and Principal Accounting Officer

Filing Compare · Pure Minerals, Inc.